Syntimmune gathers $50 mln Series B in Apple Tree-led round
Waltham, Massachusetts and New York City-based Syntimmune Inc, a biotech company, has secured $50 million in Series B financing. Apple Tree Partners led the round.
21 June 2017•1 min read
Waltham, Massachusetts and New York City-based Syntimmune Inc, a biotech company, has secured $50 million in Series B financing. Apple Tree Partners led the round.
